APPLIED PHARMACEUTICAL TOXICOLOGY 2018
May 15 - 17, 2018
Merck Research Laboratories, Boston, MA
Click to Download the APT 2018 Program Guide
Plenary Speakers for 2018
 |
Kendall Frazier, PhD, DVM Director of Pathology & Senior Science Fellow, In Vitro In Vivo Translation, GSK Leveraging Toxicology Experience to Solve Problems in the Developing World |
|
 |
John Leighton, PhD Director, Division of Hematology Oncology Toxicology, Office of Hematology and Oncology Products, US Department of Health and Human Services Recent Regulatory Updates from ICH and FDA: Implications for Oncology Drugs |
|
Speakers Confirmed for 2018
Barry Astroff, Director, Novartis Institutes for BioMedical Research (NIBR)
Vladimir Bantseev, Scientist/Toxicologist, Genentech
Giulio Barteselli, Associate Medical Director, Clinical Ophthalmology, Genentech
Sarah Campion, Senior Principal Scientist, Developmental and Reproductive Toxicology, Pfizer
Steven Cassar, Senior Scientist II, AbbVie
James Chastain, Executive Director, PK Sciences-Ophthalmology, Novartis Institutes for BioMedical Research (NIBR)
Darcey Clark, Principal Scientist, Toxicology, La Jolla Pharmaceutical Company
Paul Cornwell, Senior Research Scientist, Eli Lilly
Deidre Dalmas, Principal Scientist/Toxicologist, GSK
Krista Dobo, Senior Director Genetic Toxicology, Pfizer
Kevin French, Project Toxicologist, GSK
Claudette Fuller, Senior Principal Scientist, Merck
Maia Green, Principal Scientist, Merck
Larissa Lapteva, Associate Director, Division of Clinical Evaluation, Pharmacology and Toxicology, Office of Tissues and Advanced Therapies, CBER, FDA
Dong Lee, Head of Safety Pharmacology & Toxicology, Revolution Medicines
Steven Laing, Pathologist-Scientist, Genentech
Jonathan Maher, Senior Scientist, Discovery Toxicology, Genentech
Curtis Maier, Director, Immunology, GSK
Jenny Marlowe, Senior Director, Preclinical Development, bluebird bio
Jeff Moffit, Executive Director, Toxicology, Bioverativ
John Nicolette, Senior Principal Research Scientist, AbbVie
Judith Prescott, Executive Director, Program Development, Safety Assessment, Merck
Haleh Saber, Deputy Director, (OHOP/DHOT), FDA
Proposed Sessions for the Discovery Toxicology Workshop
Session I: When Knowledge is Power: Impactful Investigative Toxicology Case Studies
Session II: Falling Off the Needle: Acute Anaphylactoid Reactions
Session III: Hot Topics in Discovery Toxicology
Proposed Sessions for the Development Toxicology Workshop
Session IV: Impurities and Occupational Exposure Limits / Health Hazard Categorization
Session V: Regulatory Guidance Development and Updates
Session VI: Key Learning from Recent Clinical Trial Experiences
Join our LinkedIn Group